Neurocrine Biosciences INC Form 4 insider transactions

Neurocrine Biosciences director Christine A. Poon was granted 2,567 restricted stock units vesting in one year.

Neurocrine Biosciences Director Shalini Sharp was granted 2,567 restricted stock units vesting in May 2027.

Neurocrine Biosciences Director Stephen A. Sherwin was granted 2,567 restricted stock units vesting in May 2027.

Neurocrine Biosciences Director George J. Morrow was granted 2,567 restricted stock units vesting in May 2027.

Neurocrine Biosciences director William H. Rastetter was granted 2,567 restricted stock units vesting in May 2027.

Neurocrine Biosciences director Leslie V. Norwalk was granted restricted stock units and stock options as part of annual compensation.

Chief Corporate Affairs Officer David W. Boyer sold 3,888 shares of Neurocrine Biosciences common stock via a 10b5-1 plan.

Neurocrine Biosciences Director Stephen A. Sherwin acquired 3,318 shares of common stock through the vesting of restricted stock units.

Neurocrine Biosciences Director Shalini Sharp acquired 1,659 shares of common stock through the vesting of restricted stock units.

Neurocrine Biosciences Director William H. Rastetter acquired 3,318 shares of common stock through the vesting of restricted stock units.

Neurocrine Biosciences Director Richard Pops acquired 3,318 shares of common stock through the vesting of restricted stock units.

Neurocrine Biosciences Director Christine Poon acquired 3,318 shares of common stock through the vesting of restricted stock units.

Neurocrine Biosciences Director Leslie V. Norwalk acquired 1,659 shares of common stock through the vesting of restricted stock units.

Neurocrine Biosciences Director George J. Morrow acquired 3,318 shares of common stock through the vesting of restricted stock units.

Neurocrine Biosciences Director Johanna Mercier acquired 3,318 shares of common stock through the vesting of restricted stock units.

Neurocrine Biosciences Director Gary Lyons acquired 1,659 shares of common stock through the vesting of restricted stock units.

Director Kevin Gorman exercised options for 205,088 shares and sold a total of 245,088 shares of Neurocrine Biosciences.

Neurocrine Biosciences Director Richard Pops exercised 15,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences Director Leslie V. Norwalk sold 3,810 shares of common stock for approximately $155.01 per share, totaling over $590,000, as part of a pre-arranged trading plan.

Neurocrine Biosciences CFO Matt Abernethy reported a gift of 2,249 common shares, reducing his direct beneficial ownership.

Neurocrine Biosciences Chief Scientific Officer Jude Onyia gifted 3,110 shares of common stock, reducing his direct beneficial ownership.

Neurocrine Biosciences Chief Corporate Affairs Officer David W. Boyer acquired shares through RSU vesting and had shares withheld for tax obligations.

Neurocrine Biosciences' Chief Commercial Officer, Eric Benevich, reported the future vesting of restricted stock units and subsequent share withholding for tax obligations.

Neurocrine Biosciences' CFO, Matt Abernethy, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Neurocrine Biosciences' Chief Human Resources Officer, Julie Cooke, reported the vesting of 1,741 restricted stock units and the withholding of 997 shares for tax obligations.

Neurocrine Biosciences' Chief Regulatory Officer, Ingrid Delaet, reported the vesting of 801 restricted stock units and the withholding of 475 shares for tax obligations.

Neurocrine Biosciences CEO Kyle Gano reported the vesting of 2,927 restricted stock units and the withholding of 1,580 shares for tax obligations.

Neurocrine Biosciences Director Kevin Gorman reported the vesting of restricted stock units and subsequent share withholding for tax obligations.

Neurocrine Biosciences' Chief Legal Officer, Darin Lippoldt, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, reported the routine vesting of restricted stock units and subsequent tax withholding on January 31, 2026.